Cargando…

NSCLC patients with rare EGFR Ex19del/G724S mutation showed good response to afatinib combined with chemotherapy treatment: A two-case report

EGFR G724S mutation in exon 18 has been shown to be resistant to both first- and third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs). However, we found a rare mutation of EGFR Ex19del/G724S in two patients with lung cancer who demonstrated a favorable response to...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Huilin, Yu, Qitao, Shi, Lina, Hou, Qinhan, Dan, Liang, Liang, Chuqiao, Hong, Xiaoyu, Zhao, Yun, Ning, Ruiling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9730411/
https://www.ncbi.nlm.nih.gov/pubmed/36505860
http://dx.doi.org/10.3389/fonc.2022.1054593
_version_ 1784845664284311552
author Wang, Huilin
Yu, Qitao
Shi, Lina
Hou, Qinhan
Dan, Liang
Liang, Chuqiao
Hong, Xiaoyu
Zhao, Yun
Ning, Ruiling
author_facet Wang, Huilin
Yu, Qitao
Shi, Lina
Hou, Qinhan
Dan, Liang
Liang, Chuqiao
Hong, Xiaoyu
Zhao, Yun
Ning, Ruiling
author_sort Wang, Huilin
collection PubMed
description EGFR G724S mutation in exon 18 has been shown to be resistant to both first- and third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs). However, we found a rare mutation of EGFR Ex19del/G724S in two patients with lung cancer who demonstrated a favorable response to the combination of afatinib and chemotherapy. Identified by next-generation sequencing (NGS), EGFR G724S was found from a primary and a secondary tumor biopsy, respectively. Treated with afatinib combined with chemotherapy, both patients responded well and achieved progression-free survival. Analysis of acquired mutations developed during treatment using afatinib revealed that the emergence of EGFR T790M or ALK fusion was the potential mechanism of afatinib resistance. Our study lends credence to treatment using afatinib combined with chemotherapy as a viable option for patients with Ex19del/G724S.
format Online
Article
Text
id pubmed-9730411
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-97304112022-12-09 NSCLC patients with rare EGFR Ex19del/G724S mutation showed good response to afatinib combined with chemotherapy treatment: A two-case report Wang, Huilin Yu, Qitao Shi, Lina Hou, Qinhan Dan, Liang Liang, Chuqiao Hong, Xiaoyu Zhao, Yun Ning, Ruiling Front Oncol Oncology EGFR G724S mutation in exon 18 has been shown to be resistant to both first- and third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs). However, we found a rare mutation of EGFR Ex19del/G724S in two patients with lung cancer who demonstrated a favorable response to the combination of afatinib and chemotherapy. Identified by next-generation sequencing (NGS), EGFR G724S was found from a primary and a secondary tumor biopsy, respectively. Treated with afatinib combined with chemotherapy, both patients responded well and achieved progression-free survival. Analysis of acquired mutations developed during treatment using afatinib revealed that the emergence of EGFR T790M or ALK fusion was the potential mechanism of afatinib resistance. Our study lends credence to treatment using afatinib combined with chemotherapy as a viable option for patients with Ex19del/G724S. Frontiers Media S.A. 2022-11-24 /pmc/articles/PMC9730411/ /pubmed/36505860 http://dx.doi.org/10.3389/fonc.2022.1054593 Text en Copyright © 2022 Wang, Yu, Shi, Hou, Dan, Liang, Hong, Zhao and Ning https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Wang, Huilin
Yu, Qitao
Shi, Lina
Hou, Qinhan
Dan, Liang
Liang, Chuqiao
Hong, Xiaoyu
Zhao, Yun
Ning, Ruiling
NSCLC patients with rare EGFR Ex19del/G724S mutation showed good response to afatinib combined with chemotherapy treatment: A two-case report
title NSCLC patients with rare EGFR Ex19del/G724S mutation showed good response to afatinib combined with chemotherapy treatment: A two-case report
title_full NSCLC patients with rare EGFR Ex19del/G724S mutation showed good response to afatinib combined with chemotherapy treatment: A two-case report
title_fullStr NSCLC patients with rare EGFR Ex19del/G724S mutation showed good response to afatinib combined with chemotherapy treatment: A two-case report
title_full_unstemmed NSCLC patients with rare EGFR Ex19del/G724S mutation showed good response to afatinib combined with chemotherapy treatment: A two-case report
title_short NSCLC patients with rare EGFR Ex19del/G724S mutation showed good response to afatinib combined with chemotherapy treatment: A two-case report
title_sort nsclc patients with rare egfr ex19del/g724s mutation showed good response to afatinib combined with chemotherapy treatment: a two-case report
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9730411/
https://www.ncbi.nlm.nih.gov/pubmed/36505860
http://dx.doi.org/10.3389/fonc.2022.1054593
work_keys_str_mv AT wanghuilin nsclcpatientswithrareegfrex19delg724smutationshowedgoodresponsetoafatinibcombinedwithchemotherapytreatmentatwocasereport
AT yuqitao nsclcpatientswithrareegfrex19delg724smutationshowedgoodresponsetoafatinibcombinedwithchemotherapytreatmentatwocasereport
AT shilina nsclcpatientswithrareegfrex19delg724smutationshowedgoodresponsetoafatinibcombinedwithchemotherapytreatmentatwocasereport
AT houqinhan nsclcpatientswithrareegfrex19delg724smutationshowedgoodresponsetoafatinibcombinedwithchemotherapytreatmentatwocasereport
AT danliang nsclcpatientswithrareegfrex19delg724smutationshowedgoodresponsetoafatinibcombinedwithchemotherapytreatmentatwocasereport
AT liangchuqiao nsclcpatientswithrareegfrex19delg724smutationshowedgoodresponsetoafatinibcombinedwithchemotherapytreatmentatwocasereport
AT hongxiaoyu nsclcpatientswithrareegfrex19delg724smutationshowedgoodresponsetoafatinibcombinedwithchemotherapytreatmentatwocasereport
AT zhaoyun nsclcpatientswithrareegfrex19delg724smutationshowedgoodresponsetoafatinibcombinedwithchemotherapytreatmentatwocasereport
AT ningruiling nsclcpatientswithrareegfrex19delg724smutationshowedgoodresponsetoafatinibcombinedwithchemotherapytreatmentatwocasereport